Postoperative standardized management is critical for ensuring surgical efficacy and reducing tumor recurrence risk, covering complication management, hormone replacement therapy, radiotherapy, and targeted medication. According to the Chinese Guidelines for the Diagnosis and Treatment of Pituitary Tumors (2025), standardized postoperative management increases the remission rate of functional pituitary adenomas by 30% and reduces the 5-year recurrence rate of non-functional adenomas from 40% to 15%. This chapter systematically summarizes postoperative complications, core treatment protocols, and long-term rehabilitation strategies based on updated clinical evidence.

1. Early Postoperative Complications of Pituitary Tumor Surgery

1.1 Diabetes Insipidus: The Most Common Acute Postoperative Complication

Postoperative diabetes insipidus occurs in 30%–50% of patients, mainly caused by intraoperative traction injury to the hypothalamic supraoptic nucleus or pituitary stalk, leading to insufficient antidiuretic hormone (ADH) secretion (Peking Union Medical College Hospital, 2024). Typical clinical manifestations include excessive urine output (> 4000 mL/day) and low urine specific gravity (< 1.005), which should be differentiated from osmotic diuresis secondary to hyperglycemia.

1.1.1 Graded Management Strategies

Mild diabetes insipidus (4000–6000 mL/day): Oral desmopressin 0.1 mg twice daily, targeting daily urine output below 3000 mL. Up to 72% of patients achieve remission within 1–2 weeks.

Severe diabetes insipidus (> 6000 mL/day): Intranasal desmopressin 20 μg twice daily or intravenous desmopressin 1 μg every 12 hours. Daily serum sodium monitoring is mandatory to maintain levels between 135–145 mmol/L and prevent cerebral edema secondary to severe hyponatremia (15% complication risk).

1.1.2 Dynamic Monitoring Key Points

Urine volume and specific gravity are recorded every 4 hours, combined with fasting morning serum sodium tests. Serum sodium > 145 mmol/L indicates hypernatremia requiring increased fluid supplementation (2000–2500 mL daily). A study from Beijing Tiantan Hospital demonstrated that early desmopressin intervention within 3 postoperative days shortens the duration of diabetes insipidus by 40% (average 5 days vs. 8 days in untreated cases).

1.2 Electrolyte Disorders: Secondary Complications of Diabetes Insipidus

Approximately 30% of patients with postoperative diabetes insipidus develop hyponatremia (serum sodium < 135 mmol/L) due to syndrome of inappropriate antidiuretic hormone secretion (SIADH). According to 2025 data from Huashan Hospital, serum sodium < 125 mmol/L triples the risk of cerebral edema, presenting with nausea, lethargy, and even seizure attacks (5% incidence).

Intervention Measures

Fluid restriction: Daily fluid intake is limited to < 1500 mL, with priority supplementation of 0.9% normal saline.

Sodium correction: Mild hyponatremia (130–135 mmol/L) is treated with oral sodium chloride 3–6 g daily. Moderate to severe hyponatremia (< 130 mmol/L) requires intravenous 3% hypertonic saline infusion at 50 mL/h, with serum sodium rechecked every 4 hours. The correction rate is strictly controlled below 10 mmol/L per 24 hours to avoid central pontine myelinolysis.

2. Postoperative Hormone Replacement Therapy

2.1 Stepwise Treatment for Postoperative Hypothyroidism

Postoperative hypothyroidism occurs in up to 60% of patients due to impaired pituitary TSH secretion, characterized by fatigue, cold intolerance, and constipation. Replacement therapy is initiated when serum TSH > 10 mIU/L or free T4 < 12 pmol/L.

Medication and Dosage Regulation

Levothyroxine: Initial dose 25 μg daily (halved for elderly patients), with dose adjustment every 4 weeks. The therapeutic target is TSH maintained at 1–2.5 mIU/L (< 2.5 mIU/L during pregnancy).

Monitoring schedule: Thyroid function is re-evaluated at 1, 3, and 6 months postoperatively, followed by annual routine monitoring after stabilization. Long-term overdosage increases fracture risk by 20% due to accelerated bone loss.

2.2 Stress Management for Adrenocortical Insufficiency

Up to 50% of patients develop postoperative adrenocortical insufficiency. Hydrocortisone replacement (20–30 mg/day divided into two doses) is indicated when 8 a.m. serum cortisol < 165 nmol/L.

Dose Adjustment Under Stress Conditions

Baseline physiological dose: 15 mg after breakfast and 5 mg in the afternoon for daily maintenance.

Stress dose escalation: The dose is doubled to 40–60 mg/day during infection, surgery, or other physiological stress to prevent adrenal crisis, which manifests as refractory hypotension and hyperthermia (2% incidence).

2.3 Individualized Regimens for Gonadal Hormone Deficiency

2.3.1 Female Patients

Amenorrhea and infertility: Cyclic therapy with estradiol valerate 2 mg/day plus progesterone 100 mg/day, targeting serum estradiol 20–30 pg/mL. Approximately 60% of patients restore regular menstruation after 3 months of standardized treatment.

Perimenopausal management: Sequential estrogen-progesterone therapy is recommended for patients over 45 years old to reduce osteoporosis risk. Postoperative patients have a 1.8-fold higher 5-year fracture rate than the general population.

2.3.2 Male Patients

Testosterone replacement: Oral testosterone undecanoate 40 mg/day or monthly intramuscular injection 250 mg, targeting serum testosterone > 3.5 nmol/L. Sexual function is improved in 70% of treated patients. Regular PSA monitoring is required to prevent benign prostatic hyperplasia.

3. Postoperative Radiotherapy and Targeted Medical Therapy

3.1 Indications and Timing of Postoperative Radiotherapy

Indicated Populations

Residual tumor lesions: For subtotally resected tumors with residual lesions > 5 mm, adjuvant radiotherapy increases the 5-year local control rate from 50% to 80% (Chinese Journal of Neuro-Oncology, 2024).

Malignant pituitary carcinoma: Postoperative radiotherapy with a total dose of 45–50 Gy extends the median survival from 18 months to 36 months.

Management of Radiotherapy-Related Side Effects

Pituitary hypofunction: Annual hormonal surveillance is required after radiotherapy. The 10-year cumulative incidence of hypothyroidism reaches 75%, necessitating lifelong follow-up.

Optic nerve protection: Stereotactic radiotherapy (e.g., Gamma Knife) limits optic nerve radiation dose below 8 Gy, reducing visual deterioration risk from 20% to 5%.

3.2 Targeted Medical Therapy for Functional Adenomas

3.2.1 Prolactinomas

Bromocriptine: Initial dose 0.625 mg/day with weekly gradual titration, targeting serum PRL < 20 ng/mL. 80% of microadenomas achieve tumor shrinkage. Common side effects include nausea (30%) and orthostatic hypotension (15%), which are alleviated by mid-meal administration.

Cabergoline: Weekly dose 0.5 mg, with a higher biochemical remission rate (90% vs. 75%) than bromocriptine and an extremely low risk (< 1%) of valvular heart disease.

3.2.2 Growth Hormone-Secreting Tumors

Long-acting octreotide: Monthly intramuscular injection 20 mg, achieving normalized IGF-1 levels in 60% of patients. Major adverse reactions include diarrhea (40%) and cholelithiasis (5% annual incidence).

Pegvisomant: Daily subcutaneous injection 10 mg for somatostatin-resistant cases, blocking GH receptors directly and reducing IGF-1 levels by over 30% in 85% of patients.

4. Long-Term Postoperative Follow-Up and Lifestyle Management

4.1 Imaging Follow-Up Protocol

Contrast-enhanced pituitary MRI is performed at 3 months, 1 year, and 2 years postoperatively, followed by annual surveillance. Imaging focuses on sellar residual or recurrent lesions with abnormal enhancement. The 5-year recurrence rate of microadenomas is approximately 10%.

PET/CT is reserved for suspected malignant transformation; SUVmax > 3.5 indicates invasive potential, requiring pathological confirmation.

4.2 Lifestyle Intervention Strategies

Dietary Management

Low-salt and low-fat diet: Daily salt intake < 5 g and saturated fat < 20 g to reduce postoperative hypertension risk (35% incidence).

Calcium and vitamin D supplementation: Patients with osteoporosis (T-score < −2.5) receive calcium 1000 mg/day plus vitamin D 800 IU/day, reducing vertebral fracture risk by 40%.

Exercise and Psychological Regulation

Structured exercise: Moderate aerobic exercise (brisk walking, swimming) is permitted 3 months postoperatively, 150 minutes weekly, to improve postoperative insulin resistance (25% diabetes incidence).

Mental health support: 25% of patients develop anxiety or depression (HADS score ≥ 8). Semi-annual psychological evaluation and cognitive behavioral therapy effectively reduce emotional symptom severity.

5. Postoperative Frequently Asked Questions

Q1: Is pituitary tumor surgery curative?

Not in all cases. Gross total resection of microadenomas yields a 90% cure rate. However, macroadenomas and invasive tumors carry a 5-year recurrence rate of 20%–40%. Regular annual MRI surveillance and serial hormonal monitoring are mandatory for long-term disease control.

Q2: What are the long-term postoperative sequelae and complications?

① Endocrine sequelae: Diabetes insipidus (30%–50%) and hypopituitarism (50%–60%) often require long-term or lifelong hormone replacement.

② Neurological complications: 10%–15% of patients develop visual deterioration due to optic chiasm injury; 5%–10% experience cerebrospinal fluid leakage requiring surgical repair.

③ Metabolic disorders: Postoperative diabetes mellitus occurs in 25% and osteoporosis in 40% of cases, which can be well controlled via standardized medical therapy and lifestyle modification.